Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Pablo García‐Pavía(Universidad Francisco de Vitoria), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Brian Drachman(Penn Presbyterian Medical Center), Leslie Amass(Pfizer (United States)), Franca S. Angeli(Pfizer (United States)), Arnt V. Kristen(Heidelberg University), Martin Carlsson(Pfizer (United States))
Cited by 45
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k